Want to see IN:BIOCON full AI Analyst Report?

Biocon Limited (BIOCON) Price & Analysis

16 Followers

BIOCON Stock Chart & Stats

₹364.20

₹0.80(0.22%)

At close: Jan 09 4:00 PM EST

₹364.20

₹0.80(0.22%)

Day’s Range― - ―

52-Week Range₹331.00 - ₹440.30

Previous CloseN/A

Volume1.20M

Average Volume (3M)208.50K

Market Cap

₹653.64B

Enterprise Value₹685.56B

Total Cash (Recent Filing)₹38.83B

Total Debt (Recent Filing)₹154.34B

Price to Earnings (P/E)150.0

Beta0.75

Next Earnings

Aug 06, 2026

EPS Estimate

1.01

Next Dividend Ex-DateN/A

Dividend Yield0.12%

Share Statistics

EPS (TTM)2.79

Shares Outstanding1,620,907,700

10 Day Avg. Volume177,351

30 Day Avg. Volume208,504

Financial Highlights & Ratios

PEG Ratio-1.92

Price to Book (P/B)1.45

Price to Sales (P/S)2.92

P/FCF Ratio-94.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)7.92

Revenue Forecast (FY)₹199.26B

Bulls Say, Bears Say

Bulls Say

Revenue Growth & Diversified PortfolioBiocon’s sustained multi-year revenue expansion and presence across biologics, biosimilars, APIs and CDMO create durable revenue diversification. That breadth lowers reliance on a single product, supports scale economics, and sustains long-term R&D and commercial investment capacity across therapeutic areas.

Improving Leverage / Balance SheetA notably lower debt-to-equity ratio strengthens financial flexibility and reduces interest burden versus prior years. Improved leverage supports capital spending on biologics capacity, lowers refinancing risk, and provides a firmer platform for partnerships and long-cycle product investments over the medium term.

Manufacturing Scale & Vertical IntegrationIn-house large-scale fermentation, biologics manufacturing and integrated API-to-formulation capabilities provide durable competitive advantages: better cost control, quality assurance, and faster commercialization. This vertical integration supports biosimilar scale-up, contract manufacturing wins and margin retention over time.

Bears Say

Negative Free Cash FlowA materially negative free cash flow reduces internal funding for R&D, capacity expansion and commercialization. Persistent FCF deficits can force external financing or slower investment pacing, increasing vulnerability during product setbacks or competitive pricing pressure and weakening resilience.

Margin Compression & Low ROESteep margin deterioration and minimal ROE signal weakening profitability and poor capital efficiency. Over time this reduces retained earnings available for reinvestment, undermines the case for scaling commercial footprint, and increases sensitivity to cost or pricing pressures across markets.

Weak Cash Conversion / Earnings QualityLow cash conversion and earnings not translating into cash imply volatile earnings quality. This limits the company’s ability to self-fund product launches or absorb delays, may raise funding costs, and makes long-term planning and partner negotiations more difficult if cash performance lags reported profits.

Biocon Limited News

Biocon makes Biocon Biologics a wholly owned unit via share swap

Biocon Limited ( ($IN:BIOCON) ) has provided an update. Biocon Limited has acquired 11,536,956 equity shares of its...

12d ago

Biocon Makes Biocon Biologics Wholly Owned Via Preferential Share Issue

An announcement from Biocon Limited ( ($IN:BIOCON) ) is now available. Biocon Limited has completed the acquisition of...

12d ago

Biocon Closes Insider Trading Window Ahead of June Quarter Results

Biocon Limited ( ($IN:BIOCON) ) has shared an update. Biocon Limited has announced the closure of its trading...

14d ago

Biocon Deepens Malaysia Diabetes Push as Partner Wins MYR 225 Million Insulin Tenders

Biocon Limited ( ($IN:BIOCON) ) just unveiled an announcement. Biocon has reinforced its presence in Malaysia’s diabetes care...

18d ago

Biocon Sets Final Dividend and Outlines TDS Rules for FY 2025-26 Payout

Biocon Limited ( ($IN:BIOCON) ) just unveiled an update. Biocon Limited has informed shareholders that its board has...

19d ago

Biocon Subsidiary Wins Health Canada Nod for Antifungal Micafungin Injection

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Pharma Limited, a subsidiary of Biocon...

2M ago

Biocon Seeks Shareholder Nod for Leadership Changes and Preferential Share Issue via E-Voting

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Limited has initiated a postal ballot...

2M ago

Biocon Reshapes Board and Governance as It Integrates with Biocon Biologics

Biocon Limited ( ($IN:BIOCON) ) has shared an announcement. Biocon’s board approved the audited standalone and consolidated financial...

2M ago

Biocon Delivers Double-Digit Growth in Q4 as Biosimilars Lead Revenue Gains

Biocon Limited ( ($IN:BIOCON) ) has issued an update. Biocon reported consolidated Q4FY26 total income of Rs 4,569...

2M ago

Biocon Clears FY26 Results, Dividend and Board Overhaul to Drive Biologics Integration

Biocon Limited ( ($IN:BIOCON) ) has shared an announcement. Biocon’s board has approved its audited standalone and consolidated...

2M ago

BIOCON FAQ

What was Biocon Limited’s price range in the past 12 months?

Biocon Limited lowest stock price was ₹331.00 and its highest was ₹440.30 in the past 12 months.

What is Biocon Limited’s market cap?

Biocon Limited’s market cap is ₹653.64B.

When is Biocon Limited’s upcoming earnings report date?

Biocon Limited’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.

How were Biocon Limited’s earnings last quarter?

Biocon Limited released its earnings results on May 07, 2026. The company reported ₹1.2 earnings per share for the quarter, beating the consensus estimate of ₹1.174 by ₹0.026.

Is Biocon Limited overvalued?

According to Wall Street analysts Biocon Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Biocon Limited pay dividends?

Biocon Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.12%. See more information on Biocon Limited dividends here

What is Biocon Limited’s EPS estimate?

Biocon Limited’s EPS estimate is 1.01.

How many shares outstanding does Biocon Limited have?

Biocon Limited has 1,620,907,700 shares outstanding.

What happened to Biocon Limited’s price movement after its last earnings report?

Biocon Limited reported an EPS of ₹1.2 in its last earnings report, beating expectations of ₹1.174. Following the earnings report the stock price went up 0.486%.

Which hedge fund is a major shareholder of Biocon Limited?

Currently, no hedge funds are holding shares in IN:BIOCON

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biocon Limited

Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.